These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma. Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699 [TBL] [Abstract][Full Text] [Related]
8. Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review. Kapagan T; Aksu F; Yuzkan S; Bulut N; Erdem GU J Oncol Pharm Pract; 2024 Jan; 30(1):201-205. PubMed ID: 37321205 [TBL] [Abstract][Full Text] [Related]
9. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308 [TBL] [Abstract][Full Text] [Related]
10. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774 [TBL] [Abstract][Full Text] [Related]
11. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D Front Oncol; 2021; 11():749064. PubMed ID: 34900695 [TBL] [Abstract][Full Text] [Related]
14. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162 [TBL] [Abstract][Full Text] [Related]
15. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors. Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613 [TBL] [Abstract][Full Text] [Related]
16. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189 [TBL] [Abstract][Full Text] [Related]
17. Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab. Zhou H; Xie X; Zhang T; Yang M; Zhou D; Yang T Front Immunol; 2022; 13():850540. PubMed ID: 35401563 [TBL] [Abstract][Full Text] [Related]
18. Central nervous system adverse events of immune checkpoint inhibitors. Farina A; Villagrán-García M; Vogrig A; Joubert B Curr Opin Neurol; 2024 Jun; 37(3):345-352. PubMed ID: 38483130 [TBL] [Abstract][Full Text] [Related]